Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2026)
Lyell Immunopharma recorded quarterly Income from Continuing Operations of 42067000.0 in Q1 2026, up 66.34% quarter-over-quarter from 124968000.0 in Q4 2025, and up 21.38% year-over-year from 34658005.25 in Q1 2025.
Lyell Immunopharma's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 42067000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 21.38% year-over-year to 42067000.0; the TTM figure through Mar 2026 stood at 244886000.0 (up 27.86% YoY), while the FY2025 annual figure was 256324000.0, up 23.41% from the prior year.
- Income from Continuing Operations came in at 42067000.0 for Q1 2026 at Lyell Immunopharma, up from 124968000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11331000.0 in Q4 2022 to a low of 196227000.0 in Q4 2024.
- A 5-year average of 60978705.88 and a median of 52424000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 76.0% in 2022 and tumbled 362.66% in 2023, its largest moves.
- Lyell Immunopharma's Income from Continuing Operations stood at 11331000.0 in 2022, then sank by 362.66% to 52424000.0 in 2023, then slumped by 274.31% to 196227000.0 in 2024, then jumped by 36.31% to 124968000.0 in 2025, then surged by 66.34% to 42067000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 42067000.0, 124968000.0, and 33987000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -42.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.07 Mn |
| Dec 31, 2025 | -124.97 Mn |
| Sep 30, 2025 | -33.99 Mn |
| Jun 30, 2025 | -43.86 Mn |
| Mar 31, 2025 | -53.51 Mn |
| Dec 31, 2024 | -196.23 Mn |
| Sep 30, 2024 | -44.54 Mn |
| Jun 30, 2024 | -45.16 Mn |
| Mar 31, 2024 | -48.76 Mn |
| Dec 31, 2023 | -52.42 Mn |
| Sep 30, 2023 | -52.43 Mn |
| Jun 30, 2023 | -60.64 Mn |
| Mar 31, 2023 | -58.06 Mn |
| Dec 31, 2022 | -11.33 Mn |
| Sep 30, 2022 | -64.19 Mn |
| Jun 30, 2022 | -36.31 Mn |
| Mar 31, 2022 | -68.18 Mn |
| Dec 31, 2021 | -47.22 Mn |
| Sep 30, 2021 | -48.89 Mn |
| Jun 30, 2021 | -62.49 Mn |
| Mar 31, 2021 | -55.02 Mn |
| Dec 31, 2020 | -38.90 Mn |
| Sep 30, 2020 | -35.75 Mn |
| Jun 30, 2020 | -100.69 Mn |